Topical antiviral formulations

摘要

The present invention relates to formulations of nucleotide reverse transcriptase inhibitors (NRTIs), preferably [2-(6-Amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir, PMPA), or a physiologically functional derivative thereof, suitable for topical application and their use in the prevention of HIV infections.

主权项

1. A method for prophylactically reducing a risk of HIV transmission and/or infection during sexual activity between two animals, wherein at least the first animal is infected with HIV, which comprises administering to the second animal an effective amount of a topical formulation comprising an effective amount of a nucleotide reverse transcriptase inhibitor (NRTI) in combination with a pharmaceutically acceptable vehicle, wherein the NRTI further comprises [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir) or a physiologically functional derivative thereof, and the topical formulation further comprises a vaginal gel formulation comprising:[2-(6-amino-purin-9-yl)-1-methyl-1.00 (% w/w)ethoxymethyl]-phosphonic acidHydroxyethylcellulose2.50Propylparaben0.02methylparaben0.18edetate disodium0.05glycerin20.00citric acid1.00purified water75.25.